Category Venues

ACTA Inconsistent With European Law, Legal Experts Say

The recently completed Anti-Counterfeiting Trade Agreement (ACTA) is not fully consistent with European Union law and goes beyond international law in some of its aspects, concluded a group of intellectual property law experts from universities in Germany, the United Kingdom, the Netherlands, France and Spain.

WHO R&D Financing Committee Approved With Controversial Industry Expert

World Health Organization members yesterday struck a compromise allowing a Swiss industry representative to sit on a committee selecting proposals for research and developing financing for neglected diseases, disregarding the fact that he is author of one of the proposals. Special safeguards were added to prevent undue influence, but questions remain for some about a conflict of interest.

WHO Members Show Dismay At Delay On Counterfeit Medicines Group

World Health Organization members today raised strong concerns that a working group they mandated last May to address problems with WHO policy on counterfeit and substandard medicines has yet to be formed - with four months remaining before it must report back to members.

One delegation called for a halt to WHO activities on anti-counterfeiting until the outcome of the working group is accepted by member states.

New Rules Eyed For Election Of WHO Director General

With the World Health Organization director general’s term of office ending next year, WHO members today set up a drafting group to try to reconcile divergent views on the process leading to the election. Some countries are in favour of a principle of geographical rotation - citing over 60 years of no representation from their regions, while some other countries claimed rotation could override more important selection criteria such as expertise and experience, and could endanger the organisation’s future.

WHO Future In Question; Debate Over Industry Representation

A seemingly overworked and impoverished World Health Organization opened its Executive Board session today with calls for reform amid deep concerns about its financial future. Meanwhile, dissension arose over an industry representative named by the WHO secretariat to a new research and development funding working group, sparking the WHO director general to cast doubt on the role of industry in such groups.

Fair Usage In Caribbean Intellectual Property

A panoramic view of the IP situation in the Caribbean would present to the observer a carnival of Olympic size replete with politicians, diplomats, rights advocates, consumer groups, law enforcement, and impotent jurists, all gyrating discordantly to the WIPO band while Caribbean citizens look on, or are pulled or shoved in, writes Abiola Inniss.

Europe’s Outlook For 2011: EU Patent, Digital Content, Innovation And Free Trade

The Digital Agenda's hoped-for role as a key growth driver for Europe’s flagging economy has pushed intellectual property issues into a high-priority spot on the EU’s policy agenda for 2011. In an effort to boost job creation and innovation, the European Commission is looking to improve online content licensing, access and protection. And despite continuing opposition from several countries, the long-awaited European patent is finally moving forward. Debate is also heating up on new ways to encourage biomedical innovation, and on a proposed EU-India free trade pact.

The 2011 Drug Patent ‘Cliff’ And The Evolution Of IP Valuation

In today’s global economy, there is an increasing convergence of intellectual property and finance. Wall Street is grappling with how to recognise the true value of a firm’s intellectual property. Companies are realising that simply accumulating patents does not necessarily increase their firms’ value, but it is how those patents are used that can attract capital. And drug companies facing massive numbers of upcoming patent expiries, a deflated economy and other market pressures, are looking to diversify their portfolios to stay in the black.